P
Palle Petersen
Researcher at University of California, San Diego
Publications - 17
Citations - 3377
Palle Petersen is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Atrial fibrillation & Warfarin. The author has an hindex of 11, co-authored 17 publications receiving 3310 citations.
Papers
More filters
Journal ArticleDOI
Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study.
TL;DR: The incidence of thromboembolic complications and vascular mortality were significantly lower in the warfarin group than in the aspirin and placebo groups, which did not differ significantly.
Journal ArticleDOI
Diffusion tensor imaging during recovery from severe traumatic brain injury and relation to clinical outcome: a longitudinal study.
Annette Sidaros,Aase W. Engberg,Karam Sidaros,Matthew George Liptrot,Margrethe Herning,Palle Petersen,Olaf B. Paulson,Terry L. Jernigan,Egill Rostrup +8 more
TL;DR: Findings support that DTI is a clinically relevant biomarker in TBI, which may have prognostic value and also might serve as a tool for revealing changes in the neural tissue during recovery.
Journal ArticleDOI
Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study.
Annette Lemche Gulløv,Birgitte Gade Koefoed,Palle Petersen,Trine Sander Pedersen,Ellen Damgaard Andersen,John Godtfredsen,Gudrun Boysen +6 more
TL;DR: The results do not justify a change in the current recommendation of adjusted-dose warfarin (INR, 2.0-3.0) for stroke prevention in atrial fibrillation.
Journal ArticleDOI
Bleeding During Warfarin and Aspirin Therapy in Patients With Atrial Fibrillation The AFASAK 2 Study
TL;DR: The small number of major bleeding events in patients receiving adjusted-dose warfarin therapy as compared with those receiving less intensive antithrombotic treatments and the finding of no significant influence of age on the risk for bleeding indicate that even elderly patients with atrial fibrillation tolerate adjusted- dose warfar in therapy.
Journal ArticleDOI
A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin.
Carl van Walraven,Robert G. Hart,George A. Wells,Palle Petersen,Peter J. Koudstaal,Annette Lemche Gulløv,Beppie S. P. Hellemons,Birgitte G. Koefed,Andreas Laupacis +8 more
TL;DR: Irrespective of age, patients with AF and none of these 4 clinical features and who take aspirin have stroke rates comparable to those of age-matched community cohorts and would not benefit substantially from anticoagulation.